Novavax, a global vaccine company, began evaluating NVX-CoV2373 in human studies in May 2020 and the pivotal placebo-controlled phase 3 studies started in November 2020; five clinical studies provided adult and adolescent clinical data for over 31,000 participants who were administered NVX-CoV2373. This extensive data has demonstrated a well-tolerated response to NVX-CoV2373 and high vaccine efficacy against mild, moderate, or severe COVID-19 using a two-dose series (Dunkle et al., 2022) [1], (Heath et al., 2021) [2], (Keech et al., 2020) [3], (Mallory et al., 2022) [4]. The most common adverse events seen after administration with NVX-CoV2373 were injection site tenderness, injection site pain, fatigue, myalgia, headache, malaise, arthralgia, nausea, or vomiting. In addition, immunogenicity against variants of interest (VOI) and variants of concern (VOC) was established with high titers of ACE2 receptor-inhibiting and neutralizing antibodies in these studies (EMA, 2022) [5], (FDA, 2023) [6]. Further studies on correlates of protection determined that titers of anti-Spike IgG and neutralizing antibodies correlated with efficacy against symptomatic COVID-19 established in clinical trials (p < 0.001 for recombinant protein vaccine and p = 0.005 for mRNA vaccines for IgG levels) (Fong et al., 2022) [7]. Administration of a booster dose of the recombinant protein vaccine approximately 6 months following the primary two-dose series resulted in substantial increases in humoral antibodies against both the prototype strain and all evaluated variants, similar to or higher than the antibody levels observed in phase 3 studies that were associated with high vaccine efficacy (Dunkle et al., 2022) [1], (Mallory et al., 2022) [4]. These findings, together with the well tolerated safety profile, support use of the recombinant protein vaccine as primary series and booster regimens.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.vaccine.2023.07.040 | DOI Listing |
High expression of cellular self-activated immunosuppressive molecules and extensive infiltration of suppressive immune cells in the tumor microenvironment are the main factors contributing to glioma's resistance to immunotherapy. Nonetheless, technology to modify the expression of glioma cellular self-molecules through gene editing requires further development. This project advances cell therapy strategies to reverse the immunosuppressive microenvironment of glioma (TIME).
View Article and Find Full Text PDFClin Interv Aging
December 2024
Department of Anesthesiology, People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, People's Republic of China.
Background: Remimazolam, a novel ultra-short-acting benzodiazepine, shows promise for procedural sedation. This study compared the cognitive recovery of remimazolam versus propofol in elderly patients undergoing colonoscopy.
Patients And Methods: In this prospective, randomized, double-blind, controlled trial, 228 patients aged ≥ 65 years undergoing outpatient colonoscopies were recruited.
Plast Reconstr Surg Glob Open
December 2024
From the Nuñez Villar Plastic Surgery Clinic, Vallecito Arequipa, Peru.
Background: Gluteal hypoplasia and ptosis reduction are common concerns among patients seeking optimal body contouring in Peru and other countries. Although silicone implants are a traditional solution, they are not suitable for all patients. Fat grafting has emerged as an alternative, with various techniques aimed at enhancing fat graft viability and patient safety.
View Article and Find Full Text PDFJ Am Soc Mass Spectrom
December 2024
School of Electronic and Information Engineering, Soochow University, Suzhou 215006, China.
Tandem mass spectrometry (MS) is one of the most effective methods to obtain the structures of organic molecules, enabling the observation of multigenerational ion fragments. Collision-induced dissociation (CID) is currently the most mature technique for mass spectrometry analysis. Ion trap mass spectrometry (ITMS) is favored for on-site detection field, due to its ability of MS analysis with a single trap and its small size.
View Article and Find Full Text PDFACS Appl Mater Interfaces
December 2024
Institute of Optoelectronics Technology, Key Laboratory of Luminescence and Optical Information, Beijing Jiaotong University, Beijing 100044, China.
This work explores the carrier recombination dynamics of AC-driven quantum dot (QD) light-emitting diodes (AC-QLEDs) and proposes their application in the field of electric field contactless detection. Different sequences of green QD (GQD)/red QD (RQD) bilayer thin films as the emission layer of AC-QLEDs were fabricated via film transfer printing to ensure the complete morphology of each layer. AC-QLEDs with the emission layer as the sequence of GQD + RQD (GR-QLEDs) show a significantly enhanced carrier recombination efficiency due to its stable energy level structure, achieving the highest peak brightness ever recorded for vertically emitting brightness of 1648.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!